Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years: Results from 2 randomized controlled trials

অনুরূপ উপাদানগুলি

• Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study
  অনুযায়ী: Romanowski, Barbara, অন্যান্য
  প্রকাশিত: (2015)
• Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18–25 years: Results from a randomized controlled trial
  অনুযায়ী: Zhu, Feng-Cai, অন্যান্য
  প্রকাশিত: (2014)
• Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years
  অনুযায়ী: Einstein, Mark H, অন্যান্য
  প্রকাশিত: (2011)
• A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years
  অনুযায়ী: Schwarz, Tino F., অন্যান্য
  প্রকাশিত: (2019)
• Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial
  অনুযায়ী: Hu, Shangying, অন্যান্য
  প্রকাশিত: (2020)